TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07497087: A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Oral Nerandomilast Treatment in Patients With Systemic Sclerosis (SSc)

Sponsor: Boehringer Ingelheim · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 448 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT07497087 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07497087 Rescue Dossier →